Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 815-821

  Moebus, Volker J ^a,d   Stein, Renate ^a   Kieback, Dirk G ^b   Runnebaum, Ingo B ^a   Sass, G ^c   Kreienberg, Rolf ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MEDAC GMBH   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

Carboplatin; Cell lines; Cisplatin; Drug screening assays; Drugs investigational; Ovariar neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ORGANOMETALLIC COMPOUND; PACLITAXEL; PLATINUM DERIVATIVE; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; VANADOCENDICHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030966129     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. MC Guire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al: Cyclophosphamide and cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334: 1-6, 1996.
2. Thigpen JT, Blessing JA, Ball H, Hummel SJ. Barret RJ: Phase II trial of Paclitaxel in patients with progressive ovarian carcinoma after Platinum-based chemotherapy. A Gynecologic Oncology Group Study. J Clin Oncol 12: 1748-1753, 1994.
3. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5: 495-505, 1994.
4. Koepf-Maier P and Koepf H: Tumor inhibition by titanocene complexes: activity against B16 melanoma and colon 38 carcinoma Arzneim-Forsch/Drug res 37: 532-534, 1987.
5. Koepf-Maier P: Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas. J Cancer Res Clin Oncol 113: 342-348, 1987.
6. Moebus V, Gerharz CD, Press U, Moll R, Beck T. Mellin W et al: Morphological immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52: 76-84, 1992.
7. Moebus VJ, Moll R, Gerharz CD, Kieback DG. Weikel W. Hoffmann G et al: Establishment of new ovarian and colon carcinoma cell lines: Differentiation is only possible by cytokeratin analysis. Br J Cancer 69: 422-428, 1994.
8. Moehus V, Kother T, Kieback D. Crombach G. Kreienberg R: Untersuchungen zur Wirksamkeit von Cisplatin und Carboplatin an permanenten humanen Ovarialkarzinomzellinien. Tumordiagn Ther 14: 132-137, 1993.
9. Gaver RC, Colombo N, Green MD, George AM, Deeb G, Morris AD et al: The disposition of carboplatin in ovarian cancer patients Cancer Chemother Pharmacol 22: 263-270, 1988.
10. Albrecht M, Simon WE, Hölzel F: Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy. J Cancer Res Clin Oncol 109: 210-216, 1985.
11. Köpf-Maier P, Hesse B, Köpf H: Tumorhemmung durch Metallocene: Wirkung von Titanocen- Zirconocen- und Hafnocendichlorid gegenuber Ehrlich-Aszites-Tumor der Maus. J Cancer Res Clin Oncol 96: 43-51, 1980.
12. deVries EGE, Hamilton TC, Lind M, Dauplat J, Neijt JP, Ozols RF: Drug resistance, supportive care and dose intensity Ann Oncol 4: (Suppl) 57-62, 1993.
13. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Sem Oncol 18: 222-232, 1991.
14. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P et al: Improved therapeutic index of carhoplatin plus cyclophosphamide: Final report by the South-West Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706-717, 1991
15. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 10: 718-726, 1992.
16. Vermorken JB, ten Bokker Huinink WW, Eisenhauer EA. Favalli G, Belpomme D, Conte PF et al: Carboplatin versus cisplatin. Ann Oncol 4 (Suppl): 41-48, 1993.
17. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR: Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534, 1989.
18. Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis(-diammino) (1,1-cyclobutanedicarboxylato)-platinum (II) and cis-diammine-dichloroplatinum (II) on L 1210 cells. Cancer Res 45: 4043-4047, 1985.
19. Kopf-Maier P: Antitumor Bis(cyclopentadienyl)metal complexes. In: Keppler BK, ed. Metal Complexes in Cancer Chemotherapy. VCH Weinheim-New York-Basel 261-296, 1993.
20. Kleinermann ES, Zwelling LA, Muchmore AV: Enhancement of naturally occuring human spontaneous monocyte-mediated cytotoxicity by cisdiamminedichloroplatinurn (II). Cancer Res 40: 3099-3102, 1980.
21. Harstrick A, Schmoll H-J, Sass G, Poliwoda H, Rustum Y: Titanucendichloride activity in Cisplatin and Doxorubicin-resistant human ovarian carcinoma cell lines. Eur J Cancer 29A: 1000-1002. 1993.